(Q41564943)

3 October 2017

title

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting (English)

1 reference

3 October 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

9

Michael P Manns

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

10

Heiner Wedemeyer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

11

Markus Cornberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

Christoph Höner Zu Siederdissen

13 June 2020

1

object named as

Christoph Höner Zu Siederdissen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Katja Deterding

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Kerstin Port

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Lisa Sollik

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Carola Mix

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Janina Kirschner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Janet Cornberg

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

2 February 2015

1 reference

3 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1845-1852

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

Global epidemiology and genotype distribution of the hepatitis C virus infection

13 June 2020

cites work

1 reference

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

21 January 2018

1 reference

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

21 January 2018

1 reference

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis

21 January 2018

1 reference

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

21 January 2018

1 reference

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

21 January 2018

1 reference

Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

21 January 2018

1 reference

ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

21 January 2018

1 reference

Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents.

21 January 2018

1 reference

Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease.

21 January 2018

1 reference

Strategies to manage hepatitis C virus (HCV) disease burden.

21 January 2018

1 reference

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

21 January 2018

1 reference

Restoration of HCV-specific CD8+ T cell function by interferon-free therapy

21 January 2018

1 reference

Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy

21 January 2018

1 reference

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12774

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25556625%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1 reference